Moderna has delivered a genuine clinical success in high-risk melanoma. Whether that success can be turned into a commercially viable product — one manufactured individually for each patient — is a separate matter, and it is the question now driving the debate on Wall Street.
The Phase III INTerpath-001 trial enrolled 1,137 patients whose high-risk melanoma had been fully surgically removed. Adding intismeran autogene to Merck’s Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone, and reduced the risk of distant metastasis or death by 38%. After two years, 82.2% of patients on the combination were relapse-free and alive, against 70.0% in the comparator arm.
Those are substantial figures rather than a faint signal of hope. Still, precision matters about what was actually measured: the endpoints were composite. Fewer relapses or deaths within such an endpoint does not by itself prove the treatment extends life. Overall survival data are not yet mature. Severe treatment-related adverse events occurred in 14.2% of patients on the combination, compared with 13.4% in the control group — a difference that argues against dismissing the tolerability profile, without settling anything.
A Beat, Not a Blowout
Reuters reported that analysts had gone into the medical congress looking for a reduction in recurrence risk of at least 40%. The delivered figure was 42%. The trial therefore cleared that bar, but not by a wide margin. A study can succeed medically without satisfying every additional hope the equity market had layered on top of it.
The stock’s reaction told its own story. Shares fell 1.1% on the day, and did not stabilize after the initial selloff. Bernstein, which reaffirmed its neutral rating on Thursday, read the pullback as profit-taking following the release of a long-awaited piece of news — a characterization that sits alongside, rather than contradicts, the more cautious reading from Citi.
Citi Puts the Manufacturing Burden in Focus
Geoff Meacham of Citi reiterated his sell recommendation on Thursday with a price target of $80.00. His reservation was not about whether the data are convincing, but about whether the benefit justifies the work of collecting tumor material from each patient and producing a personalized therapy. He also pointed to expectations for broader oncology success.
Should investors sell immediately? Or is it worth buying Moderna?
That shifts the investor question beyond efficacy. A positive readout does not automatically answer the economic one. Bloomberg reported that investors were particularly doubtful about how well the results will transfer to other cancer types. RBC analyst Trung Huynh considered approval likely but the commercial outcome considerably less certain. Approvability, commercial success and efficacy in further tumors are three distinct questions, and the melanoma study does not resolve all of them at once. Extending the current win to other indications will require their own data.
The Regulatory Path Is Still Being Paved
Moderna and Merck are in talks with regulators about possible approval steps; the vaccine is not yet approved. Chief executive Stéphane Bancel said the companies are preparing a US marketing application, according to Reuters. NPR reported that Merck intends to file with the FDA, with a decision potentially arriving at the end of 2027 — a possibility, not a confirmed approval date.
The full presentation is scheduled for the ESMO congress in Madrid, and Moderna has convened an oncology investor event alongside it, giving the company a stage to lay out its perspective beyond the headline numbers. The next confirmed financial milestone comes on November 6, 2026, when Moderna reports third-quarter 2026 results — a reminder that the oncology narrative and the balance sheet will both be under scrutiny.
On the clinical front, Moderna has moved forward. The most defensible stance is neither euphoria nor blanket skepticism, but a willingness to credit the demonstrated melanoma benefit while withholding any certainty premium from the opportunities still open.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 24 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 24.
Moderna: Buy or sell? Read more here...
